Tetracyclines, sulfonamides and metronidazole;Tetraciclinas, sulfamidas y metronidazol

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 21, Issue 9, 2003, Pages 520-529+533

  Pérez Trallero, Emilio ^a   Iglesias, Luis ^a  

^a HOSPITAL DONOSTIA   (Spain)

Author keywords

Metronidazole; Sulfonamides; Tetracyclines

Indexed keywords

4 NITROIMIDAZOLE; ALCOHOL; AMINO ACID; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CARBAMAZEPINE; CHLORTETRACYCLINE; CLOMOCYCLINE; CONTRACEPTIVE AGENT; DEMECOLCINE; DIGOXIN; DNA; DOXYCYCLINE; LYMECYCLINE; METACYCLINE; METHOTREXATE; METRONIDAZOLE; MINOCYCLINE; NATURAL PRODUCT; OXYTETRACYCLINE; PENICILLIN G; PHENFORMIN; PHENYTOIN; RIFAMPICIN; RNA; ROLITETRACYCLINE; SULFONAMIDE; TETRACYCLINE DERIVATIVE;

ABDOMINAL CRAMP; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; APPETITE DISORDER; ARTHRALGIA; ATAXIA; BACTERIOSTASIS; BACTERIUM; BRAIN TOXICITY; COLITIS; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DNA SYNTHESIS INHIBITION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG USE; EDEMA; EXFOLIATIVE DERMATITIS; FEVER; GASTROINTESTINAL TOXICITY; GLOSSITIS; HEADACHE; HUMAN; HYPOPLASIA; INSOMNIA; IRRITABILITY; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; MEDICINE; MICROORGANISM; NAUSEA; NEURITIS; NONHUMAN; PAIN; PARASITOSIS; PHLEBITIS; PHOTOSENSITIVITY DISORDER; PIGMENTATION; PROTEIN SYNTHESIS; PRURITUS; RASH; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TINNITUS; TOOTH MALFORMATION; TOXICITY; URTICARIA; VERTIGO; VESTIBULAR DISORDER; VOMITING; WORLD HEALTH ORGANIZATION;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DNA REPLICATION; HUMANS; METRONIDAZOLE; MOLECULAR STRUCTURE; PARASITIC DISEASES; SULFANILAMIDES; TETRACYCLINES;

EID: 0344872551     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13052338     Document Type: Review

References (33)

1. Klein NC, Cunha BA. Tetracyclines. Med Clin North Am 1995;79:789-801.
2. Joshi N, Miller DQ. Doxycycline revisited. Arch Intern Med 1997;157:1421-8.
3. Smilack JD. The tetracyclines. Mayo Clin Proc 1999;74:727-9.
4. Chopra I, Roberts M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001;65:232-60.
5. th ed. Philadelphia: Churchill Livingstone, 2003; p. 393-406.
6. Lazaro Bengoa E, Madurga Sanz M, Abajo Iglesias FJ. Evolución del consumo de antibióticos en España, 1985-2000. Med Clin (Barc) 2002;118:561-8.
7. a edición. Lista Modelo de la OMS (revisada en abril de 2003). http://www.who.int/medicines/organization/par/edl/expeom13/eml13_sp.pdf (accesible agosto 2003)
8. Chopra I. New developments in tetracycline antibiotics: Glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist Updat 2002;5:119-25.
9. Betriu C, Rodrfguez-Avial I, Ali Sánchez B, Gómez M, Alvarez J, Picazo JJ. In Vitro Activities of Tigecycline (GAR-936) against Recently Isolated Clinical Bacteria in Spain. Antimicrob Agents Chemother 2002;46:892-5.
10. Roberts MC. Resistance to tetracycline, macrolide-lincosamide-streptogramin, trimethoprim, and sulfonamide drug classes. Mol Biotechnol 2002;20:261-83.
11. Ross JI, Shelling AM, Eady EA, Cove JH, Cunliffe WJ, Leyden JJ, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001;144:339-46.
12. Roberts MC. Tetracycline therapy: Update. Clin Infect Dis 2003;36:462-7.
13. Goulden V. Guidelines for the management of acne vulgaris in adolescents. Paediatr Drugs 2003;5:301-13.
14. Bell DM, Kozarsky PE, Stephens DS. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis 2002;8:222-5.
15. Pradines B, Spiegel A, Rogier C, Tall A, Mosnier J, Fusai T, et al. Antibiotics for prophylaxis of Plasmodium falciparum infections: In vitro activity of doxycycline against Senegalese isolates. Am J Trop Med Hyg 2000;62:82-5.
16. Skold O. Sulfonamide resistance: Mechanisms and trends. Drug Resist Updat 2000;3:155-60.
17. Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis 2001;32:1608-14.
18. th ed. Philadelphia: Churchill Livingstone, 2003; p. 385-92.
19. Masters PA, O'Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003;163:402-10.
20. Martin JN, Rose DA, Hadley K, Perdreau-Remington F, Lam PK, Gerberding JL. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era. J Infect Dis 1999;180:1809-18.
21. Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs 1997;54:679-708.
22. Martinez V, Caumes E. Metronidazole. Ann Dermatol Venereol 2001;128:903-9.
23. th ed. Philadelphia: Churchill Livingstone, 2003; p. 385-92.
24. Raether W, Hanel H. Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res 2003;90 (Supp 1):19-39.
25. Samuelson J. Why metronidazole is active against both bacteria and parasites. Antimicrob Agents Chemother 1999;43:1533-41.
26. Land KM, Johnson PJ. Molecular basis of metronidazole resistance in pathogenic bacteria and protozoa. Drug Resist Updat 1999;2:289-94.
27. Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev 2001;14:150-64.
28. Hedberg M, Nord CE, The ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 2003;9:475-88.
29. Brazier JS, Hall V, Morris TE, Gal M, Duerden BI. Antibiotic susceptibilities of Gram-positive anaerobic cocci: Results of a sentinel study in England and Wales. J Antimicrob Chemother 2003;52:224-8.
30. López-Brea M, Martínez MJ, Domingo D, Alarcón T. A 9 year study of clarithromycin and metronidazole resistance in Helicobacterpylori from Spanish children. J Antimicrob Chemother 2001;48:295-7.
31. Haggoud A, M'Hand RA, Reysset G, El M'Daghri N, Benbachir M, Moumni M. Prevalence and characteristics of nim genes encoding 5-nitroimidazole resistance among Bacteroides strains isolated in Morocco. Microb Drug Resist 2001;7:177-81.
32. Bereswill S, Krainick C, Stahler F, Herrmann L, Kist M. Analysis of the rdxA gene in high-level metronidazole-resistant clinical isolates confirms a limited use of rdxA mutations as a marker for prediction of metronidazole resistance in Helicobacter pylori. FEMS Immunol Med Microbiol 2003;36:193-8.
33. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR 2002;51:1-80.